There is no current evidence published on drugs modulating NAPE-PLD, FAAH, and MAGL expression with anti-obesity-like effects, even though several molecules have been developed to treat CNS-related pathologies. Here, FAAH is linked to obesity due to melanocortin 4 receptor deficiency.